ABOLIGO LIMITED
Company number 15752547 · Monitor this company
Free AI analysis
Have an AI read this company's filings and write an assessment — financial health, risks, and what the numbers say.
Shareholders' funds
£1,579,808
Balance sheet as at 2026-05-31
Overview
- Company type
- Private Limited Company
- Incorporated
- 2024-05-31
- Employees
- 5 (2026 accounts · was 1 in 2025)
- Registered office
- Moneta, Building 280, Room 2031 Babraham, Cambridge, England, CB22 3AT
- Postcode
- CB22 3AT
- Capital
- 2 GBP
- Accounts category
- Total Exemption Full
Accounts
- Last made up to
- 2026-05-31
- Next due by
- 2028-02-29
- Financial year end
- 31 May
Confirmation statement
- Last statement dated
- 2026-05-30
- Next due by
- 2027-06-13
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 4 current
Karen Miller RYAN
Director
Nicolas Steven, Dr GEE
Director
Nicholas James, Dr HUTCHINGS
Director
Brian Kishore CARPENTER
Director
Contact details
- Website
- aboligo.com
Re-imagining antibody-oligonucleotide conjugate (AOC) manufacturing to accelerate multiplex analysis.
Among its peers
Top 25%
by shareholders' funds, of 234 similar companies in CB
Trading since 2024.
Competitors Cambridge
This company ranks 52 among research and experimental development on biotechnology in Cambridge.